Publications by authors named "A Enshaei"
Article Synopsis
- Risk stratification is essential for treating acute lymphoblastic leukemia (ALL) and involves creating an optimal prognostic model using factors like white blood cell count and minimal residual disease (MRD).
- Using data from four national clinical trials, researchers developed the European Working Group for Adult ALL prognostic index (EWALL-PI) to assess patient risk, finding that it accurately correlated with relapse and death rates.
- The EWALL-PI risk model outperformed existing algorithms and successfully differentiated patients into standard and high-risk groups, with high-risk patients showing significantly higher rates of relapse and lower survival.
Chromothripsis, the process of catastrophic shattering and haphazard repair of chromosomes, is a common event in cancer. Whether chromothripsis might constitute an actionable molecular event amenable to therapeutic targeting remains an open question. We describe recurrent chromothripsis of chromosome 21 in a subset of patients in blast phase of a myeloproliferative neoplasm (BP-MPN), which alongside other structural variants leads to amplification of a region of chromosome 21 in ∼25% of patients ('chr21amp').
View Article and Find Full Text PDFPurpose: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant.
Methods: Data were collected for consecutive CYP (age 1-24 years) with Philadelphia chromosome-positive or Philadelphia chromosome-negative B-ALL who received Blina as first-line therapy. Blina was given as replacement for postremission intensive chemotherapy to patients with chemotherapy intolerance or resistance.